Sélectionnez votre pays ou région

Vous êtes maintenant en France (Français)
Accueil / À propos d'Arjo / Investors / Newsroom / Arjo interim report January-June 2022
The share Arjo B 12 juil. 2024 17:29 3,66 EUR (-0,38%)
❮ Actualités

Arjo interim report January-June 2022

“Market demand remains healthy and the order book for capital equipment continues to be significantly above last year’s levels. Performance in the quarter is held back by short-term challenges due to postponed sales in patient handling, significantly lower critical care rental volumes in the US compared with last year, and continued supply chain disruptions,” says Joacim Lindoff, President & CEO of Arjo.

“We have a continued positive momentum within many areas and our underlying business continues to develop well. We estimate that growth will gradually increase in the year’s final two quarters and the outlook of 3-5% organic growth for the full-year remains unchanged,” concludes Joacim Lindoff.

April-June 2022 in brief

  • Net sales increased to SEK 2,404 M (2,199).
    Net sales grew organically by 0.2%.
  • Adjusted EBITDA amounted to SEK 430 M (513).
  • Adjusted operating profit amounted to SEK 165 M (275).
  • Profit after financial items amounted to SEK 139 M (253).
  • Earnings per share amounted to SEK 0.38 (0.70).
  • Cash flow from operations amounted to SEK 158 M (431).
  • Cash conversion was 37.4% (84.8).
  • Arjo awarded rental contract position with HealthTrust in the US.


Telephone conference

Fund managers, analysts and the media are invited to a teleconference on July 14 at 08.00 CEST. Please see details below to join the conference:

Sweden: +46 8 505 163 86

USA: +1 412 317 6300

UK: +44 20 319 84884

Pin code: 4127122# (to be used for all numbers)


A presentation will be held during the telephone conference. To access the presentation, please use this link:

Alternatively, use the following link to download the presentation:

A recording of the teleconference will be available for 90 days via the following link:


For more information, please contact:

Maria Nilsson, Acting EVP Marketing Communication & Public Relations

Tel: +46 734 244 515

Email: maria.nilsson@arjo.com  


Sara Ehinger, VP Investor Relations & Corporate Communications

Tel: +46 723 597 794

Email: sara.ehinger@arjo.com


This information is information that Arjo AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 07:00 CEST on July 14, 2022.

About Arjo

At Arjo, we believe that empowering movement within healthcare environments is essential to quality care. Our products and solutions are designed to promote a safe and dignified experience through patient handling, medical beds, personal hygiene, disinfection, diagnostics, and the prevention of pressure injuries and venous thromboembolism. With 6,500 people worldwide and 65 years caring for patients and healthcare professionals, we are committed to driving healthier outcomes for people facing mobility challenges. www.arjo.com  

Arjo interim report January-June 2022
Bienvenue sur le site d’Arjo

Si vous souhaitez obtenir des informations complémentaires sur nos solutions, n’hésitez pas à contacter le responsable commercial de votre secteur à l’aide du lien « contactez-nous » ci-dessous.

Êtes-vous un professionnel de santé?